Search Results - "TOTO, Robert D"

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease by Chertow, Glenn M, Vart, Priya, Jongs, Niels, Toto, Robert D, Gorriz, Jose Luis, Hou, Fan Fan, McMurray, John J V, Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C David, Stefánsson, Bergur V, Langkilde, Anna Maria, Wheeler, David C, Heerspink, Hiddo J L

“…In the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized, placebo-controlled trial, the sodium-glucose…”
Get full text

Addition of Angiotensin Receptor Blockade or Mineralocorticoid Antagonism to Maximal Angiotensin-Converting Enzyme Inhibition in Diabetic Nephropathy by MEHDI, Uzma F, ADAMS-HUET, Beverley, RASKIN, Philip, VEGA, Gloria L, TOTO, Robert D

“…Aldosterone promotes glomerular and tubular sclerosis independent of angiotensin II in animal models of diabetic nephropathy. Most human studies testing the…”
Get full text

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics by Wheeler, David C, Stefansson, Bergur V, Batiushin, Mikhail, Bilchenko, Oleksandr, Cherney, David Z I, Chertow, Glenn M, Douthat, Walter, Dwyer, Jamie P, Escudero, Elizabeth, Pecoits-Filho, Roberto, Furuland, Hans, Górriz, José Luis, Greene, Tom, Haller, Hermann, Hou, Fan Fan, Kang, Shin-Wook, Isidto, Rey, Khullar, Dinesh, Mark, Patrick B, McMurray, John J V, Kashihara, Naoki, Nowicki, Michal, Persson, Frederik, Correa-Rotter, Ricardo, Rossing, Peter, Toto, Robert D, Umanath, Kausik, Van Bui, Pham, Wittmann, István, Lindberg, Magnus, Sjöström, C David, Langkilde, Anna Maria, Heerspink, Hiddo J L

“…Abstract Background The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD; NCT03036150) trial was designed to assess the…”
Get full text

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial by Persson, Frederik, Rossing, Peter, Vart, Priya, Chertow, Glenn M., Hou, Fan Fan, Jongs, Niels, McMurray, John J.V., Correa-Rotter, Ricardo, Bajaj, Harpreet S., Stefansson, Bergur V., Toto, Robert D., Langkilde, Anna Maria, Wheeler, David C., Heerspink, Hiddo J.L.

“…OBJECTIVE The Dapagliflozin and Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) study demonstrated risk reduction for kidney and…”
Get full text

SGLT-2 Inhibition: A Potential New Treatment for Diabetic Kidney Disease? by Toto, Robert D

“…Diabetic nephropathy is the leading cause of kidney failure. Treatments with drugs that block the renin-angiotensin system have proven beneficial in slowing…”
Get more information

Longitudinal Progression Trajectory of GFR Among Patients With CKD by Li, Liang, PhD, Astor, Brad C., PhD, Lewis, Julia, MD, Hu, Bo, PhD, Appel, Lawrence J., MD, MPH, Lipkowitz, Michael S., MD, Toto, Robert D., MD, Wang, Xuelei, MS, Wright, Jackson T., MD, PhD, Greene, Tom H., PhD

“…Background The traditional paradigm of glomerular filtration rate (GFR) progression in patients with chronic kidney disease (CKD) is a steady nearly linear…”
Get full text

Serum renin and major adverse kidney events in critically ill patients: a multicenter prospective study by Flannery, Alexander H, Ortiz-Soriano, Victor, Li, Xilong, Gianella, Fabiola G, Toto, Robert D, Moe, Orson W, Devarajan, Prasad, Goldstein, Stuart L, Neyra, Javier A

“…Preliminary studies have suggested that the renin-angiotensin system is activated in critical illness and associated with mortality and kidney outcomes. We…”
Get full text

Serum IL-17 levels are higher in critically ill patients with AKI and associated with worse outcomes by Collett, Jason A, Ortiz-Soriano, Victor, Li, Xilong, Flannery, Alexander H, Toto, Robert D, Moe, Orson W, Basile, David P, Neyra, Javier A

“…Interleukin-17 (IL-17) antagonism in rats reduces the severity and progression of AKI. IL-17-producing circulating T helper-17 (TH17) cells is increased in…”
Get full text

Hyperkalemia treatment modalities: A descriptive observational study focused on medication and healthcare resource utilization by Desai, Nihar R, Rowan, Christopher G, Alvarez, Paula J, Fogli, Jeanene, Toto, Robert D

“…Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy has been shown to improve outcomes among patients with congestive heart failure, diabetes, or…”
Get full text

Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA ® ): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk by Rosenstock, Julio, Perkovic, Vlado, Alexander, John H, Cooper, Mark E, Marx, Nikolaus, Pencina, Michael J, Toto, Robert D, Wanner, Christoph, Zinman, Bernard, Baanstra, David, Pfarr, Egon, Mattheus, Michaela, Broedl, Uli C, Woerle, Hans-Juergen, George, Jyothis T, von Eynatten, Maximilian, McGuire, Darren K

“…Cardiovascular (CV) outcome trials in type 2 diabetes (T2D) have underrepresented patients with chronic kidney disease (CKD), leading to uncertainty regarding…”
Get full text

Prevalence of Major Depressive Episode in CKD by Hedayati, S. Susan, MD, MHSc, Minhajuddin, Abu T., PhD, Toto, Robert D., MD, Morris, David W., PhD, Rush, A. John, MD

“…Background Depression is prevalent in long-term dialysis patients and is associated with death and hospitalization. Whether depression is present through all…”
Get full text

Association of Blood Pressure Increases During Hemodialysis With 2-Year Mortality in Incident Hemodialysis Patients: A Secondary Analysis of the Dialysis Morbidity and Mortality Wave 2 Study by Inrig, Jula K., MD, MHS, Patel, Uptal D., MD, Toto, Robert D., MD, Szczech, Lynda A., MD, MSCE

“…Background Intradialytic increases in blood pressure (BP) can complicate the management of hypertension in hemodialysis (HD) patients. However, the long-term…”
Get full text

Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA-CKD Trial by Chertow, Glenn M, Correa-Rotter, Ricardo, Vart, Priya, Jongs, Niels, McMurray, John J V, Rossing, Peter, Langkilde, Anna Maria, Sjöström, C David, Toto, Robert D, Wheeler, David C, Heerspink, Hiddo J L

“…Background The DAPA-CKD (Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease) trial (NCT03036150) demonstrated that dapagliflozin…”
Get full text

The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists by Provenzano, Michele, Jongs, Niels, Vart, Priya, Stefánsson, Bergur V., Chertow, Glenn M., Langkilde, Anna Maria, McMurray, John J.V., Correa-Rotter, Ricardo, Rossing, Peter, Sjöström, C. David, Toto, Robert D., Wheeler, David C., Heerspink, Hiddo J.L.

“…Mineralocorticoid receptor antagonists (MRAs) and sodium–glucose cotransporter-2 (SGLT2) inhibitors reduce the risk of kidney failure in chronic kidney disease…”
Get full text

Alport Syndrome Classification and Management by Warady, Bradley A., Agarwal, Rajiv, Bangalore, Sripal, Chapman, Arlene, Levin, Adeera, Stenvinkel, Peter, Toto, Robert D., Chertow, Glenn M.

“…Alport syndrome affects up to 60,000 people in the United States. The proposed reclassification of thin basement membrane nephropathy and some cases of focal…”
Get full text

Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes by Tuttle, Katherine R, Bakris, George L, Toto, Robert D, McGill, Janet B, Hu, Kuolung, Anderson, Pamela W

“…OBJECTIVE:--Ruboxistaurin selectively inhibits protein kinase C-{szligbeta} and ameliorates kidney disease in animal models of diabetes. The purpose of this…”
Get full text

Validation of Depression Screening Scales in Patients With CKD by Hedayati, S. Susan, MD, MHSc, Minhajuddin, Abu T., PhD, Toto, Robert D., MD, Morris, David W., PhD, Rush, A. John, MD

“…Background Depressive symptoms, assessed by using self-report scales, are present at a striking rate of 45% in patients with chronic kidney disease (CKD) at…”
Get full text

Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease by Jain, Nishank, MD, MPH, Li, Xilong, PhD, Adams-Huet, Beverley, MS, Sarode, Ravi, MD, Toto, Robert D., MD, Banerjee, Subhash, MD, Hedayati, S. Susan, MD, MHSc

“…Thrombotic events while receiving antiplatelet agents (APAs) are more common in subjects with versus without chronic kidney disease (CKD). Data on antiplatelet…”
Get full text

Potassium Handling with Dual Renin-Angiotensin System Inhibition in Diabetic Nephropathy by Van Buren, Peter N, Adams-Huet, Beverley, Nguyen, Mark, Molina, Christopher, Toto, Robert D

“…Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are the cornerstones of pharmacologic therapy in diabetic nephropathy…”
Get full text

C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT) by Mc Causland, Finnian R., MBBCh, MMSc, MRCPI, Claggett, Brian, PhD, Burdmann, Emmanuel A., MD, PhD, Eckardt, Kai-Uwe, MD, Kewalramani, Reshma, MD, Levey, Andrew S., MD, McMurray, John J.V., MD, Parfrey, Patrick, MD, Remuzzi, Giuseppe, MD, Singh, Ajay K., MD, Solomon, Scott D., MD, Toto, Robert D., MD, Pfeffer, Marc A., MD, PhD

“…Background To better understand a potential association of elevated C-reactive protein (CRP) level with progression of chronic kidney disease (CKD), we…”
Get full text